Crystal Pharmatech Launches OEB4/OEB5 High-Potency Laboratory, Expanding Global CDMO Capabilities for Complex Drug Development

By: PRLog

April 28, 2026 at 12:00 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

New Suzhou facility complements existing U.S. infrastructure, delivering dual-continent containment capabilities for high-potency API programs

SUZHOU, China - April 28, 2026 - PRLog -- Crystal Pharmatech, a global leader in solid-state and formulation science, today announced the official launch of its new OEB4/OEB5 high-potency laboratory at its headquarters in Suzhou, China. The facility has successfully passed rigorous third-party exposure control testing and is now fully operational.

The state-of-the-art laboratory features full-room negative pressure containment, dedicated gowning areas, an independent exhaust system, and five high-performance isolators compliant with ISPE standards and JG/T385:2012. It is equipped with advanced instrumentation including XRPD, TGA, DSC, and high-precision analytical balances to support safe solid-state research and crystallization under containment.

This new Suzhou facility complements Crystal Pharmatech's existing OEB4/OEB5 capabilities at its U.S. site in Cranbury, New Jersey, creating seamless dual-continent support for highly potent APIs (HPAPIs), including oncology and targeted small-molecule therapies.

Clients can now access integrated early-stage services such as Mol2Med™ Developability Assessment, polymorph screening, solid-state characterization, single crystal structure determination, preformulation, and small-scale crystallization process development (≤20 g) in a fully contained environment.

The expansion strengthens Crystal Pharmatech's position as a trusted global CDMO partner, helping biotech companies reduce development risks, accelerate timelines, ensure operator safety, and advance complex drug programs with confidence.

About Crystal Pharmatech

Crystal Pharmatech provides end-to-end solid-state and formulation solutions from preclinical to clinical stages, with operations in China, the United States, and Canada.

Contact
Crystal Pharmatech Co., Ltd.
***@crystalpharmatech.com

Photos: (Click photo to enlarge)

Source: Crystal Pharmatech Co., Ltd.

Read Full Story - Crystal Pharmatech Launches OEB4/OEB5 High-Potency Laboratory, Expanding Global CDMO Capabilities for Complex Drug Development | More news from this source

Press release distribution by PRLog

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	268.26	+3.20 (1.21%)
AAPL	280.14	+8.79 (3.24%)
AMD	360.54	+6.05 (1.71%)
BAC	53.24	-0.22 (-0.41%)
GOOG	383.22	+1.28 (0.34%)
META	608.75	-3.16 (-0.52%)
MSFT	414.44	+6.66 (1.63%)
NVDA	198.45	-1.12 (-0.56%)
ORCL	171.83	+10.44 (6.47%)
TSLA	390.82	+9.19 (2.41%)

Symbol

Price

Change (%)

AMZN

268.26

+3.20 (1.21%)

AAPL

280.14

+8.79 (3.24%)

AMD

360.54

+6.05 (1.71%)

BAC

53.24

-0.22 (-0.41%)

GOOG

383.22

+1.28 (0.34%)

Crystal Pharmatech Launches OEB4/OEB5 High-Potency Laboratory, Expanding Global CDMO Capabilities for Complex Drug Development

More News

Recent Quotes